Eric Scott Schaefer

3.8k citations
30 papers · 2.8k · 2 hit papers · h-index 15

Impact in

  • Oncology top 1%
    • Lung Cancer Research Studies
    • Cancer Immunotherapy and Biomarkers
    • Peptidase Inhibition and Analysis
    • Pancreatic and Hepatic Oncology Research
    • Neuroendocrine Tumor Research Advances

Papers in

    • Lung Cancer Research Studies 6
    • Cancer Immunotherapy and Biomarkers 3
    • Peptidase Inhibition and Analysis 2
    • Colorectal Cancer Treatments and Studies 2

Eric Scott Schaefer

28 papers receiving 2.8k citations

Eric Scott Schaefer's Hit Papers

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 2020 · 516 citations
5160+2+4Years since publication50010001.5k

Peers

Eric Scott Schaefer
Comparison fields: 5 of 83
  • Oncology 2.1k
  • Epidemiology 726
  • Pulmonary and Respiratory Medicine 398
  • Transplantation 31
  • Immunology 169
Replace Bernd Doerken with:
Bernd Doerken Germany
Darren Tayama United States
Roberta Cerutti Italy
Bradley Aaron Krasnick United States
Steven N. Wolff United States
Clare M. Faul Germany
Virginie Huchet France
Galina Statsenko Russia
Ahmet DEMİRKAZIK Türkiye
Paul Cannell Australia
Eric Scott Schaefer relative to Bernd Doerken Germany Bernd Doerken's profile →
Citations per field
00.5×10×20×33.7×
Bernd Doerken · 1×
Citations per year

Countries citing papers authored by Eric Scott Schaefer

Since Specialization
Citations

This map shows the geographic impact of Eric Scott Schaefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Scott Schaefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Scott Schaefer more than expected).

Fields of papers citing papers by Eric Scott Schaefer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Scott Schaefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Scott Schaefer. The network helps show where Eric Scott Schaefer may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Scott Schaefer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Scott Schaefer Line = papers co-authored together Eric Scott Schaefer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
20191711
2
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
2020516
3 2011164
4 202371
5 201138
6 202135
7 201133
8 201333
9 202222
10 202421
11 201218
12 201618
13 201818
14 201417
15 201816
16 202115
17 202112
18 201211
19 202311
20 20206

About Eric Scott Schaefer

Eric Scott Schaefer is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Surgery and Rheumatology, having authored 30 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (6 papers), Cancer Immunotherapy and Biomarkers (3 papers), Organ Transplantation Techniques and Outcomes (2 papers), Peptidase Inhibition and Analysis (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers), Chronic Disease Management Strategies (1 paper) and Renal Transplantation Outcomes and Treatments (1 paper). The work is most often cited by research in Oncology (2.1k citations), Epidemiology (726 citations), Pulmonary and Respiratory Medicine (398 citations), Transplantation (31 citations) and Immunology (169 citations). Eric Scott Schaefer has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include April D. Armstrong, Stephanie F. Coquia, Matthew D. Budge, Gregory S. Lewis, Donald J. Flemming, Megan K. Moore, Christopher S. Hollenbeak, Tadahiro Uemura, Zakiyah Kadry and Christina S. Baik. Their work appears in journals such as Annals of Oncology, Transplant International, Clinical Lung Cancer, JCO Oncology Practice and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact